Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) 是一种鸟苷酸环化酶 (sGC),单胺氧化酶 A (MAO-A) 和 NO 合酶 (NOS) 抑制剂。Methylene blue trihydrate 是一种血管加压药,在医疗中通常用作染料。Methylene blue trihydrate 具有抗伤害感受,抗疟疾,抗抑郁和抗焦虑作用,可用于高铁血红蛋白血症,神经退行性疾病和异环磷酰胺引起的脑病的研究。
生物活性 | Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is aguanylyl cyclase (sGC),monoamine oxidaseA (MAO-A)andNO synthase(NOS)inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures. Methylene blue trihydrate has antinociception, antimalarial, antidepressant and anxiolytic activity effects. Methylene Blue trihydrate has the potential for methemoglobinemias, neurodegenerative disorders and ifosfamide-induced encephalopathytreatment[1][2][3]. |
IC50& Target | |
体外研究 (In Vitro) | By acting as an alternative electron acceptor/donor Methylene blue restores mitochondrial function, improves neuronal energy production and inhibits the formation of superoxide[1]. Methylene blue inhibits cytochrome P450 (CYP) isozymes. Methylene blue is an odorless, water soluble, dark blue-green crystalline powder, which turns blue whenever mixed in solution. Methylene blue is a vasopressor that impacts the NO synthetic pathway by inhibiting inducible NOS and inhibiting the subsequent activation of sGC. In addition, by binding to the iron heme moiety of sGC and causing enzyme inhibition, Methylene blue blocks accumulation of cyclic GMP (cGMP), competing directly with NO in its ability to activate soluble guanylyl cyclase[3].
|
体内研究 (In Vivo) | Methylene Blue (1, 5, and 25 μg/rat) significantly decreases sevoflurane minimum alveolar anesthetic concentration (MAC) and brain cyclic guanosine monophosphate (cGMP) content in a dose-dependent manner in male Sprague-Dawley rats (7-week-old, 200-250 g)[2]. Methylene blue is used as a dye in chromoendoscopy, and is sprayed onto the mucosa of the gastrointestinal tract in order to identify dysplasia, or pre-cancerous lesions[2]. Methylene blue is able to restore vascular tone, normalize mean arterial pressures (MAP), and reduce vasopressor usage[3].
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | 亚甲蓝三水合物;亚甲基蓝三水合物;次甲基蓝三水合物 |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(267.45 mM;Need ultrasonic) 配制储备液 1 mM | 2.6745 mL | 13.3726 mL | 26.7451 mL | 5 mM | 0.5349 mL | 2.6745 mL | 5.3490 mL | 10 mM | 0.2675 mL | 1.3373 mL | 2.6745 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.69 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.69 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (6.69 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.69 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|